Inhalation anesthesia market size is at a lucrative CAGR of 3.5% over the forecast period

January 11, 2021 - The global inhalation anesthesia market size is projected to reach USD 1.42 billion by 2015, at a lucrative CAGR of 3.5% over the forecast period. Key factors contributing to its rapid growth include increasing prevalence of cancer, cardiovascular, respiratory, neurological, gastrointestinal, orthopedic, and spinal diseases and disorders.

Furthermore, increasing number of emergency cases and demand for short stay ambulatory day care surgical procedure are amongst critical success factors attributed to the market growth. Access to universal health insurance coverage for a wider population base coupled with constant improvements in healthcare infrastructure in various developing countries are expected to positively impact the number of surgeries performed, thus increasing the usage of inhalation anesthetics.

In-Depth research report on Inhalation Anesthesia market:
https://www.radiantinsights.com/research/inhalation-anesthesia-market

On the basis of product, the inhalation anesthesia market is classified into sevoflurane, isoflurane, and desflurane. These products are used for induction and maintenance of anesthesia for patients during surgical procedures. Sevoflurane led the product segment in 2018 and is anticipated to grow at a lucrative rate over the forecast period, attributed to its therapeutic advantages, low cost, and higher potency for the induction of anesthesia. On the other hand, isoflurane is expected to witness the fastest CAGR of 6.3% over the forecast period, due to its increasing use in maintenance of anesthesia for treatment of weak or geriatric patients owing to its sparing effect on cardiovascular function.

On the basis of regions, the market is broadly classified into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa (MEA). North America held the leading market share of USD 456.0 million and is anticipated to witness lucrative CAGR over the forecast period. This is owing to increasing prevalence of chronic diseases coupled with the presence of advanced healthcare facilities. On the other hand, Asia Pacific was anticipated to witness the fastest CAGR of 4.0% due to increasing population and number of patients suffering from chronic population.

Some of the key players operating in this market include Halocarbon Products Corporation; Baxter; Hikima Pharmaceuticals PLC; Lunan Pharmaceutical Group Co. Ltd.; Piramal Enterprises Limited; Jiangsu Hengrui Medicine Co. Ltd.; Fresenius Kabi AG, and AbbVie Inc.

Further key findings from the report suggest:

• Sevoflurane product segment led the market in terms of revenue, valued at USD 768.6 million, in 2018

• Isoflurane product segment is anticipated to expand at the fastest CAGR of 6.3% owing to its increasing use in the treatment of weak and geriatric patients owing to its low effect on cardiovascular function

• North America led the market in 2018 with a revenue of USD 456.0 million owing to the presence of advanced healthcare facilities, strong reimbursement scenario, and prevalence of chronic diseases

• Key players operating in the inhalation anesthesia market include Halocarbon Products Corporation; Baxter; Hikima Pharmaceuticals PLC; Lunan Pharmaceutical Group Co. Ltd.; Piramal Enterprises Limited; Jiangsu Hengrui Medicine Co. Ltd.; Fresenius Kabi AG, and AbbVie Inc.

To get free request sample:
https://www.radiantinsights.com/research/inhalation-anesthesia-market/request-sample

Global legal marijuana market is anticipated to expand at a CAGR of 18.1%

November 24, 2020 - The global legal marijuana market size is expected to reach USD 73.6 billion by 2027. It is anticipated to expand at a CAGR of 18.1% during the forecast period. Increasing legalization of cannabis for medical as well as adult-use is expected to promote growth.

On the basis of type, the medical segment held the leading revenue share of 71.0% in 2019, owing to the growing adoption of cannabis as a pharmaceutical product for treating severe medical conditions, such as cancer, arthritis, and Parkinson’s disease and Alzheimer’s disease among other neurological conditions. Moreover, increasing need for pain management therapies along with growing disease burden of chronic pain among elders is expected to boost the product demand.

In-Depth research report on Legal Marijuana market:
https://www.radiantinsights.com/research/legal-marijuana-market

Based on product type, the legal marijuana buds segment accounted for the largest market share in terms of revenue and was valued at USD 9.1 billion in 2019. Buds are primary plant products and are readily available without any processing, which makes them relatively affordable for low-income patients. Moreover, the rapid onset of action of smoking buds compared to other types is anticipated to further fuel the segment growth.

Based on medical applications, the chronic pain segment dominated the legal marijuana market in 2019 owing to presence of a large patient pool. On the other hand, mental disorder application is expected to witness the fastest growth over the forecast period owing to the growing number of patients suffering from mental disorders, such as anxiety disorder, depressions, and Alzheimer’s disease.

Based on geography, North America held the largest revenue share at 88.4% in 2019, owing to the increasing legalization of medical marijuana and liberalism of government regulations regarding the same. The legalization of medical cannabis Canada, Israel, and some countries in Europe and South America, owing to its multiple therapeutic applications is expected to promote the growth. Moreover, the recent legalization of cannabis for medical purposes in countries like Australia, Germany, and Poland is expected to create lucrative opportunities for market stakeholders.

Further key findings from the report suggest:

• Based on marijuana type, the medical segment held the largest market share of 71.0% in 2019 owing to the increasing use of the product for the treatment of cancer and other medical conditions

• By product type, the buds segment hold the largest market share in 2019 with a revenue of USD 9.1 billion owing to the easy availability of buds than other products

• Key players operating in the legal marijuana market include Aurora Cannabis; Canopy Growth Corporation; Maricann Group, Inc.; GW Pharmaceuticals, plc.; Aphria, Inc.; Tilray; The Cronos Group; ABcann Medicinals, Inc.; Lexaria Corp.; and Organigram Holding, Inc.

To get free request sample:
https://www.radiantinsights.com/research/legal-marijuana-market/request-sample

Growing geriatric population is expected to positively impact the overall market for antacid

November 03, 2020 - The global antacid market size is expected to reach USD 7.91 billion by 2025. It is projected to expand at a CAGR of 3.9% over the forecast period. The trend of self-medication for occasional heartburn is one of the major factors driving the market.

Growing geriatric population is expected to positively impact the overall market for antacid. According to the United Nations Department of Economic And Social Affairs (DESA), the global elderly population (60 years and above), was around 962 million in 2017. This number is expected to grow at the fastest rate in Latin America with 71% increase in population aged 60 and over, followed by Asia with 66%, Africa with 64%, North America with 41%, and Europe with 23%.

In-Depth research report on Antacids market:    
https://www.radiantinsights.com/research/antacids-market

Key players operating in antacid market focus on product enhancement to cater to patient requirements, such as changing the dosage form into chewable tablets, powder, and jelly. Also, these players are involved in collaborations and acquisitions to expand their market presence. For instance, in 2017, Pfizer, Inc. entered into a strategic agreement with AstraZeneca to acquire one of the antacid brands, Neksium for a value of INR 75 crores in India to boost its product portfolio.

The easy availability of antacids over-the-counter offer growth opportunities for the sales of overall market. Some of the key players areGlaxoSmithKline plc; AstraZeneca; Pfizer, Inc.; Sun Pharmaceuticals Industries Ltd.; Dr. Reddy's Laboratories Ltd.; Bayer AG; Takeda Pharmaceutical Company Limited.

Further key findings from the report suggest:

• In 2017, tablet segment led the antacid market due to high efficacy compared to other dosage forms. Liquid is anticipated to be the fastest growing segment due to its palatable taste and preferred choice for children and elderly population

• Retail pharmacy led the distribution channel segment due its accessibility and availability. Online pharmacy is anticipated to be the fastest growing segment due to growing adoption of Pharma 3.0 and consumer awareness

• Asia Pacific is estimated to be the largest and fastest growing region over the forecast period due to presence of key players such as GlaxoSmithKline plc; Pfizer Inc.; and Abbott among others

• North America held the second largest market share in 2017 owing to increasing prevalence of different digestive disorders

• Some of the key companies operating in this market are GlaxoSmithKline plc; Bayer AG; Boehringer Ingelheim International GmbH; Dr. Reddy's Laboratories Ltd.; Reckitt Benckiser Group plc; Sun Pharmaceuticals Ltd.; Sanofi; Takeda Pharmaceutical Company Limited; Pfizer Inc.; and Procter & Gamble.

To get free request sample:
https://www.radiantinsights.com/research/antacids-market/request-sample

Global hemoglobinopathies market is projected to expand at a CAGR of 10.2% during the forecast period

October 28, 2020 - The global hemoglobinopathies market size is expected to reach USD 12.6 billion by 2026. It is projected to expand at a CAGR of 10.2% during the forecast period.

Rising prevalence of hemoglobin disorders such as Sickle Cell Disease (SCD), thalassemia, Hb C, and Hb E is estimated to be a high impact rendering driver for the market. According to the World Health Organization (WHO), hemoglobin disorders are endemic in over 60% of 229 countries affecting over 70% of births. It is also reported that minimum 5% of the world population are carriers of significant hemoglobin variation.

In-Depth research report on Hemoglobinopathies  market:    
https://www.radiantinsights.com/research/hemoglobinopathies-market

Prevalence of hemoglobinopathies is high in low-income countries from regions, such as Sub-Saharan region and South-east Asia. 85% of the affected population in U.S. and Europe has ancestral base in these regions.

Governments are collaborating with local institutes to undertake awareness programs for curbing the effect of hemoglobinopathies-related mortality rate. For instance, Sickle Cell Disease Coalition (SCDC) was founded by The American Society of Hematology (ASH) in 2016 to promote awareness for the condition and enhance outcomes for individuals.

Insufficient healthcare infrastructure and low levels of disease diagnosis and treatments are some of the key factors contributing to the increase in target population in low-income regions such as South-east Asia, Mediterranean basin, and Africa.

North America led the overall hemoglobinopathies market in terms of revenue in 2018. Growing prevalence of blood disorders, favorable government programs, and high level of awareness among healthcare professionals and patients for hemoglobinopathies-related genetic testing, are the factors attributed to the growth.

Asia Pacific is expected to witness lucrative growth over the forecast period owing to the presence of high unmet clinical needs, improving healthcare infrastructure, and rising economic levels. Moreover, introduction of low-cost diagnostic alternatives for hemoglobinopathies is likely to further boost the growth.

Further key findings from the report suggest:

• SCD segment held the largest market share in 2018 owing to rising prevalence of sickle cell disease and presence of strong product pipeline such as LentiGlobin

• Genetic testing for diagnosis of sickle cell disorders is expected to witness lucrative growth over the forecast period. Increasing awareness coupled with rising government programs is anticipated to enhance the usage rates for diagnostic tests pertaining to SCD

• Pre-implant genetic diagnosis is estimated to witness lucrative CAGR of over 8.0% during the forecast period owing to rising awareness levels among the population and increasing healthcare expenditure

• Blood transfusion was the largest therapy segment for hemoglobinopathies, owing to high acceptance of this treatment option and significant success rate

• Key market players include Gamida Cell; Alnylam Pharmaceuticals; Sanofi; Sangamo Therapeutics Inc.; Global Blood Therapeutics; bluebird bio Inc.; Emmaus Life Sciences Inc.; Prolong Pharmaceuticals; and Celgene Corporation

To get free request sample:
https://www.radiantinsights.com/research/hemoglobinopathies-market/request-sample

Global in-vitro toxicology testing market size is anticipated to reach USD 30.9 billion by 2027

October 19, 2020 - The global in-vitro toxicology testing market size is anticipated to reach USD 30.9 billion by 2027 and is projected to register a CAGR of 9.2% over the forecast period. The new paradigm shift in toxicity testing of animal models toward computational methods such as silico models to interpret toxicity pathway data, drives the demand for in-vitro toxicology testing. These methods provide cost and time efficiency and enhance safety assessment.

Several governments are taking measures to minimize animal-based test models, forming conducive government policies, and providing funds to support in-vitro models. These factors are expected to create ample growth opportunities for the market. For instance, in November 2019, the U.S. National Institute for Environmental Health Sciences planned to provide funds to small companies for the development of engineered 3D culture or organotypic culture models (OCM) in-vitro systems.

In-Depth research report on In-vitro Toxicology Testing market:    
https://www.radiantinsights.com/research/in-vitro-toxicology-testing-market

With advancements in high throughput screening, biological screening, and chemical synthesis, the number of publicly available databases containing data related to toxicity; absorption, distribution, metabolism, and excretion (ADME); pharmacovigilance; and drug screening has expanded rapidly. This has enabled scientists to access vast information for toxicity profiling, thereby spurring revenue generation in this market.

Further key findings from the report suggest:

• Growing application of 3D-spheroid-cultures, particularly for nanoparticle toxicity testing, resulted in the dominance of the cell culture technology segment in 2019

• Omics technology is anticipated to register lucrative growth as RNA sequencing and shotgun proteomics are increasingly used for a more comprehensive understanding of the effects of toxicants

• The high usage rate of cellular assays with advancements in cell-based technologies, including label-free detection and high-content screening, has contributed to the dominance of the cellular assays segment in 2019

• Systemic toxicology emerged as the leading application segment in 2019 as it plays a key role in risk assessment during drug development procedures. For instance, toxicity testing of systemic immunosuppressive drugs and systemic corticosteroids is important during the development of drugs for ocular inflammatory disease

• Pharmaceutical industry dominated the in-vitro toxicology testing market in 2019 as toxicological testing is a prerequisite step for drug development

• Stringent government regulations regarding animal usage for toxicity analysis in North America have led to an increased adoption rate of in-vitro models. Hence, North America dominated the global market in 2019

• The Asia Pacific region is anticipated to witness the fastest growth rate over the forecast period due to increasing initiatives by public agencies to encourage acceptance of non-animal test models

• Abbott, Thermo Fisher, Agilent Technologies, GE Healthcare, Bio-Rad, and Merck KGaA are some of the key players operating in the market.

To get free request sample:
https://www.radiantinsights.com/research/in-vitro-toxicology-testing-market/request-sample

Protein Engineering Market to Witness Growth Acceleration During 2025

September 28, 2020 - The global protein engineering market is expected to reach USD 3.09 billion by 2025. The market is driven by presence of regulatory authorities consistently striving to reduce time and cost involved in the drug discovery process. One such example is the launch of critical path initiative by U.S. FDA, for incorporation of advanced technologies, such as protein engineering, in drug discovery processes. Moreover, this facilitates prediction of probable adverse reactions & toxicity and improves efficacy of target molecules early on, resulting in lowered drug attrition rates in the later stages. This is anticipated to help control overall expenditure. Rise in R&D expenditure by countries indicates the urgent need for adoption of these tools in all drug discovery and development processes.

In-Depth research report on Protein Engineering market:    
https://www.radiantinsights.com/research/protein-engineering-market

The rising number of government initiatives aimed at enhancing protein engineering capabilities is anticipated to present the market with high growth potential. This has resulted in a significant rise in number of research activities & programs and fund allotment for R&D. For instance, Protein Engineering Network of Centres of Excellence (PENCE) contributed approximately USD 1.0 million for proteomics projects and hosted conferences on proteomics in Canada as an effort to broaden research associated with this technology.

Further key findings from the report suggest:

• Hybrid approach is predicted to observe exponential growth as a consequence of technological superiority and ability to overcome the shortcomings associated with the aforementioned technologies

• Software & services is expected to emerge as the fastest growing segment owing to high inclination of companies to outsourcing of services to achieve overall cost-efficiency

• Monoclonal antibodies held the largest share in protein-type segment due to development of these antibodies on a large scale through extensive adoption of these engineering tools

• North America held a substantial share, which can be attributed to extensive research activities that are likely to provide high potential growth platform through consistent usage in this region

• The market in Asia Pacific is projected to exhibit exponential growth over the coming years owing to rising awareness pertaining to benefits of protein engineering and increasing disposable income

• The competition is marked by players employing strategies such as mergers & acquisitions and distribution agreements resulting in significant growth in their market share.
  

To get free request sample:
https://www.radiantinsights.com/research/protein-engineering-market/request-sample

Increasing use of cold plasma in medical treatment and rising cases of HAI are the key driving factors for the global market

September 21, 2020 - The global cold plasma market size is expected to reach USD 198.50 million by 2026 at a strong CAGR of 15.2%. Increasing use of cold plasma in medical treatment and rising cases of Hospital-Acquired Infections (HAI) are the key driving factors for the global market. In healthcare industry, plasma technology has been in use for some time and it continues to help improve various treatments. One of the major properties of cold plasma is the ability to kill bacteria and prevent infection. Therefore, it acts as an effective healing solution. It also accelerates healing process and prevent patient from discomfort.

Cold plasma is used in the treatment of chronic wounds and burns. The bacterial cells, including Multidrug Resistant (MDR) bacteria, are instantly killed after being exposed to cold plasma. As per an article published by the Medical Xpress, Med Tech Europe, around 4.0 million people in Europe suffer from non-healing wounds every year. It also reported that a burn patient in Germany was treated using prototype plasma treatment. Moreover, as per a research published by The National Center for Biotechnology Information (NCBI), a patient suffering with two second-degree burns was treated with cold plasma, which healed the itching and pain and presented new tissue after the second treatment. Such cases are anticipated to promote the usage of cold plasma in various wound treatments.

In-Depth research report on Cold Plasma market:    
https://www.radiantinsights.com/research/cold-plasma-market

Further key findings from the study suggest:

•    In terms of revenue, atmospheric pressure segment is projected to ascend at the fastest CAGR over the forecast period due to rising application scope in various medical procedures

•    Wound healing application segment is expected to witness a significant growth over the forecast period

•    Asia Pacific region is estimated to witness the highest growth due to increased adoption of technologically advanced procedures for treatment of various diseases

•    Rise in disposable income levels and growing target population base are also likely to contribute to the region's development

•    Some of the key companies in the global cold plasma market are U.S. Medical Innovations, LLC, Bovie Medical Corporation, Neoplas Tools GmbH, Europlasma N.V., and P2i Limited.

To get free request sample:
https://www.radiantinsights.com/research/cold-plasma-market/request-sample

A maturing and strongly diversified clinical pipeline is expected to contribute to the growth of stem cell market

September 18, 2020 - The global stem cell market size is expected to reach USD 15.63 billion by 2025, at a CAGR of 8.8% during the forecast period. Amplifying research studies targeted at widening the utility scope of stem cell products is anticipated to drive the growth. These research projects are set to offer new opportunities for implementation of several clinical applications of stem cells. Thus, extensive research on exploring varied applications of stem cells would impact treatment options that aid in disease-modification.

In addition, collaborations targeted at achieving robust manufacturing of high-quality differentiated cells is expected open up new avenues of market expansion over the forecast period. Rapid transition from conventional treatment methods to regenerative medicine has been observed over the past few years. Regenerative medicine is set to become the new prototype of treatment in human health having the potential to address unmet medical needs across the globe. Integration of biologics, chemical compounds, materials, and devices is witnessed in stem cell therapeutics making it an interdisciplinary field.

Browse full research report:
https://www.radiantinsights.com/research/stem-cell-market

Moreover, rising recognition of cellular therapies as an emerging revolutionary advancement has been witnessed in the healthcare industry in recent years. Business expansion is adopted by companies aiming at strengthening their portfolio regarding cellular therapy. This is expected to improve detailed understanding and future potential of stem cells for the of patients suffering from Parkinson's disease, diabetes, injuries associated with spinal cord, and other neurodegenerative disorders.

Further, a maturing and strongly diversified clinical pipeline is expected to contribute to the growth of stem cell market. Availability of latest data during the mid and late stage of the regenerative medicine clinical trials and increase in the product approvals regarding the same is expected to drive the market.

Adult stem cells displayed highest contribution in the market and is expected to maintain its dominance over the forecast period. Factors such as minimal ethical issues, lower rejection rates, and long-term renewal property associated with stem cells utility has contributed to the dominance of this segment. Moreover, the characteristic property of these cells to regenerate into malignant cells is anticipated to support the estimated share.

Scientists at Michigan State University revealed novel type of cells, named induced XEN cells, originated from a cellular trash pile in March 2016. The conclusions drawn from this research study is expected to drive emerging regenerative medicine treatment methods. In January 2019, research professionals at the University of Freiburg carried out research on the potential of mesenchymal stems cells in repairing damaged organs. This is further anticipated to boost research as well as sales in the market throughout the study period.

Further key findings from the report suggest:

• Based on application regenerative medicine is estimated to hold a substantial market share in terms of revenue over the forecast period, owing to rise in emerging pipeline projects

• Progress of acquisition technology is expected to gain momentum during the forecast period owing to the rising research projects that demand the use of harvesting techniques

• Amongst the type of therapies used, autologous therapy accounted for the largest share of the stem cell market

• Likelihood of getting new infections is less in autologous cell-based therapy, consequently enhancing its adoption

• R&D activities carried out on large scale and huge funds granted by funding bodies to advance cellular research in U.S. have made North America the dominant region in the global market

• Vast research studies taking place in Singapore and Japan is anticipated to propel the Asia Pacific market in the forthcoming years

• Osiris Therapeutics Inc.; Celgene Corporation; BIOTIME, INC.; Cynata; Advanced Cell Technology Inc.; and STEMCELL Technologies Inc.; are some of the key market players

• The companies are undergoing strategic partnership to enhance their product line. They are keen on seeking investments from overseas organizations along with adopting partnership strategies with pharmaceutical organizations, which is set to fuel the market growth.

Download free request sample:
https://www.radiantinsights.com/research/stem-cell-market/request-sample

Global Wireless Health Market is Expected to Reach USD 315.4 Billion by 2025

September 02, 2020 - The global wireless health market size is expected to reach USD 315.4 billion by 2025, exhibiting a 23.5% CAGR during the forecast period. Increase in number of eHealth initiatives worldwide, increase in penetration of smartphones and Internet connectivity, and growth in the trend of self-disease management are some of the factors boosting market growth. Growing trend toward use of wearable devices for monitoring physical parameters, such as sleep, blood pressure, heart rate, and physical activity, is also driving the wireless health market.

Growing geriatric population and subsequent rise in chronic disease burden is also driving the market. According to The Wall Street Journal, there has been an increase in usage of digital medicine, which enables management of chronic conditions such as diabetes, heart diseases, and respiratory diseases. Moreover, these digital medicines are cost-effective alternatives to traditional disease management.

In-Depth research report on Wireless Health Market:    
https://www.radiantinsights.com/research/wireless-health-market

Shifting trend toward value-based care is another factor contributing to the growth of the wireless health market. At present, some of the telehealth services, such as consulting a doctor via video connection, are reimbursed by CMS. Use of digital services such as various platforms for health management has promoted the development of various applications for managing diabetes, heart diseases, and asthma. Use of applications for chronic disease management, fitness tracking, supporting medication adherence, preventing hospital readmissions, symptom tracking, and managing mental and behavioral health are on the rise.

Further key findings from the report suggest:

• Wireless Personal Area Network (WPAN) emerged as the largest technology segment and Wireless Wide Area Network (WWAN) is anticipated to witness the fastest growth over the coming years

• Software emerged as the largest component segment owing to rise in number of research initiatives. The services segment, on the other hand, is anticipated to expand at the fastest CAGR of 24.7%

• Patient-specific applications emerged as the largest segment owing to increase in adoption and rise in research initiatives for developing them to manage individual health

• The patient segment accounted for the largest revenue share in terms of end use owing to increase in use of health and fitness applications by people around the world

• Themarket is highly fragmented with participants such as IBM; Allscripts; Cerner Corporation; Omron Corporation; Koninklijke Philips N.V.; Epic Systems Corporation; and Evolent Health, Inc.

Free request sample :
https://www.radiantinsights.com/research/wireless-health-market/request-sample

Biopharmaceutical Third Party Logistics Market - Rsing Demand for Temperature Controlled Logistic Services to Transport Biologics

August 25, 2020 - The global biopharmaceutical third party logistics market size is expected to reach USD 120.64 billion by 2025, at a CAGR 4.9% over the forecast period. The market for biopharmaceutical third party logistics (3PL) is majorly driven by rising demand for temperature controlled logistic services to transport biologics in various regions and growing distribution networks of biopharmaceutical companies to improve their sales. Rising adoption of automated storage and retrieval systems in the emerging countries is an ongoing trend in the pharmaceutical logistics companies that has gained a significant traction.

Furthermore, the trend of shifting from small molecule drugs to biopharmaceuticals, mainly vaccines and biologics, is projected to drive the market. Since, these small molecule drugs are temperature sensitive products, demand for temperature controlled transportation and storage increases and thus is responsible for the market growth. As of now, the pharmaceutical sales through distributors have grown from USD 304.6 billion in 2013 to USD 440.2 billion in 2016. However, the average number of manufacturers per distributor had declined from 1,474 in 2014 to 1,211 in 2016. This data depicts that there is an increase in quantity of pharmaceutical products being distributed, and thus, is expected to surge the demand for 3PL services.

For further inquiries, about Biopharmaceutical Third Party Logistics (3PL) Market
https://www.radiantinsights.com/research/biopharmaceutical-third-party-logistics-3pl-market 

Additionally, environmental concerns and cost have caused a slight shift in the means of transport used for commercial product, moving from airway to seaway shipping and in roadways from truck to intermodal (both rail and truck). The intermodal transport is majorly used by these pharmaceutical companies to reduce the carbon footprint. The ongoing trend shows that the pharmaceutical manufacturers have shifted towards sea freight to reduce the cost and risk factor. Although for cold chain products, the companies still prefer air freight. However, some of the large pharmaceutical companies are planning to transport 70% of their products via ocean freight including cold chain products.

Further key findings from the report suggest:

•    In 2018, non-cold chain logistics held the largest market share in terms of revenue owing to the sales of a large number of drugs that do not require any temperature control

•    Cold chain logistics segment is expected to register the faster CAGR over the forecast period owing to the demand for biologics, such as cellular therapies, vaccines, and test kits

•    Warehousing and storage held the largest market share among the types of services in 2018

•    Asia pacific expected to emerge with the fastest CAGR over the forecast period owing to adoption of medicines from aging population and shift of drug sales from brand manufacturers to generic

•    Key players operating in the biopharmaceutical third party logistics market include DHL International GmbH., SF Express, United Parcel Service of America, Inc, AmerisourceBergen Corporation, DB Schenker, Kuehne and Nagel, Kerry logistics network limited and Agility.

To get free request sample :
https://www.radiantinsights.com/research/biopharmaceutical-third-party-logistics-3pl-market/request-sample

New Study Projects Strong Growth for Global Telepresence Equipment Market

August 24, 2020 - Telepresence refers to a set of technologies which allow a person to feel as if they were present, to give the appearance of being present, or to have an effect, via telerobotics, at a place other than their true location. In the context of China-US trade war and global economic volatility and uncertainty, it will have a big influence on this market.

Telepresence Equipment Report by Material, Application, and Geography - Global Forecast to 2023 is a professional and comprehensive research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, United Kingdom, Japan, South Korea and China).

In-Depth research report on Telepresence Equipment market:    
https://www.radiantinsights.com/research/global-telepresence-equipment-market-research-report-2019-2023

In this report, the global Telepresence Equipment market is valued at USD XX million in 2019 and is projected to reach USD XX million by the end of 2023, growing at a CAGR of XX% during the period 2019 to 2023.

The report firstly introduced the Telepresence Equipment basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the world's main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

The major players profiled in this report include:

• Array telepresence
• Avaya
• Cisco Systems
• Huawei Technologies
• Polycom
• Vidyo
• ZTE Corporation

The end users/applications and product categories analysis:
On the basis of product, this report displays the sales volume, revenue (Million USD), product price, market share and growth rate of each type, primarily split into-

• Large Enterprise
• Medium Enterprise
• Small Enterprise

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Telepresence Equipment for each application, including-

• Healthcare
• Education
• Pharmaceuticals

Download free request sample :
https://www.radiantinsights.com/research/global-telepresence-equipment-market-research-report-2019-2023/request-sample

Alternative sweeteners are used as a substitute for sugar to enrich and sweeten food and beverages

August 10, 2020 - Alternative sweeteners are used as a substitute for sugar to enrich and sweeten food and beverages. These sweeteners are used mostly in reduced concentration since they are relatively sweeter than sucrose (table sugar). They are low in calorie content, making them ideal for consumption by diabetic and overweight people. Variants of alternative sweeteners like high and low-intensity sweeteners, and high-fructose syrup find application in dairy products, bakery items, carbonated drinks, and various other products. The global alternative sweetener market is anticipated to expand at a CAGR of 5.6% during the 2019-2024 period, and will reach a value of USD 17.3 Bn by 2024 from USD 13.17 Bn in 2019.

For further inquiries, about Global Alternative Sweetener Market
https://www.radiantinsights.com/research/global-alternative-sweetener-market

Segmentation based on product type

Based on product type, the high-intensity sweeteners segment accounted for the highest market share (41.0%) in 2019, since it is sweeter than sucrose and is used as diet sugar for health-conscious consumers. It was followed by the high-fructose syrup segment, with a market share of 31.2% in 2019. High-fructose syrup is available in liquid form and is used in food and beverages. The low-intensity sweeteners segment accounted for a market share of only 27.8% in 2019.

Segmentation based on applications

Based on applications, the beverage segment accounted for the highest market share (55.4%) in 2019, and is anticipated to expand at a CAGR of 5.9% during the 2019-2024 period. An increase in the consumption of diet variants of soft drinks and low-sugar beverages among health-conscious consumers is expected to fuel the growth of the beverage segment. The food segment is expected to expand at a CAGR of 5.3% during the forecast period. Changes in sugar consumption patterns and rising awareness about low-calorie sugar alternatives are anticipated to drive the food segment.

Regional insights

North America dominated the global alternative sweetener market with a share of 35.5% in 2019. It was followed by Europe because of the imposition of the sugar tax by governments. Asia-Pacific is anticipated to exhibit the highest CAGR (7.2%) during the 2019-2024 period. The consumption of sweetened food and beverages is high in the region, resulting in the increased incidence of diabetes and obesity. As a result, consumers are becoming health conscious and more inclined towards alternative sweeteners. The markets in Latin America, and the Middle East and Africa are still at nascent stages but are expected to expand significantly.

Companies profiled

- Archer Daniels Midland
- Ajinomoto
- Tate & Lyle
- Ingredion Incorporated
- Cargill
- DuPont Nutrition & Health
- Amai Proteins
- Miraculex
- Sugarlogix
- SteviaOne

To get free request sample:
https://www.radiantinsights.com/research/global-alternative-sweetener-market/request-sample

Global hemophilia market size is anticipated to register a CAGR of 5.5% over the forecast period

July 27, 2020 - The global hemophilia market size is expected to reach USD 18.1 billion by 2027. It is anticipated to register a CAGR of 5.5% over the forecast period. Increasing awareness of early diagnosis and treatment coupled with supportive government policies is anticipated to boost market share over the forecast period.

Browse full research report :
https://www.radiantinsights.com/research/hemophilia-market

For instance, the NHF (National Hemophilia Foundation) allows to find treatments for inheritable bleeding disorders and help prevent complications of these disorders through research, education, and advocacy. Their programs and initiatives are in association with the Centers for Disease Control and Prevention.

In addition, U.S. Hemophilia Treatment Center Network provides specialized healthcare centers and these offer care to address all psychological, educational, and physical needs of patients suffering from the disease. These centers currently provide care to more than 35,000 adults and children with the disease and other bleeding disorders.

The key market companies are projected to adopt strategic initiatives including geographic expansion and R&D especially in developing and underdeveloped regions, such as Middle Eastern and West African countries.

For instance, BioMarin is involved in developing Valoctocogene Roxaparvovec (BMN-270) for treating type A patients and is currently under clinical trials. Furthermore, in June 2017, the U.S. FDA accepted the investigational new drug application for Sanofi’s BIVV001 based on its preclinical study results.

Rising incidence of the disease is estimated to propel hemophilia market growth over the forecast period. According to the data published by the NHF, around 20,000 individuals in U.S. are suffering from this disease. In addition, approximately 75% of people with hemophilia receive inadequate treatment or have less/ no access to treatment globally.

Further key findings from the report suggest:

• Hemophilia A held the largest market share in 2019 due to its increasing prevalence worldwide

• Type B is expected to be the fastest growing type over the forecast period, at a CAGR of 6.8%

• On-demand dominated the treatment segment over the forecast period and is expected to contribute majority of the share in 2019

• Prophylaxis is estimated to be the fastest growing segment over the forecast period

• Replacement therapy was expected to be the largest segment in 2019

• Gene therapy dominated the therapy segment over the forecast period owing to increasing involvement of companies to develop more gene therapy for its treatment

• Increasing research and development and strategic collaborations are key strategies undertaken by major players in the market space.

To get free request sample :
https://www.radiantinsights.com/research/hemophilia-market/request-sample

Global complementary and alternative medicine market size is projected to reach USD 296.3 billion by 2027

July 23, 2020 - The global complementary and alternative medicine market size is projected to reach USD 296.3 billion by 2027, exhibiting a CAGR of 19.9%. A comparatively high demand for alternative medicine across developing countries and expanding applications of traditional medicine practiced in Asia are two key driving factors of the market. China and India are the key contributors to the Asia Pacific region and thus are offering significant momentum to the revenue generation by complementary and alternative treatment through the study period.

In-Depth research report on Complementary And Alternative Medicine market:   
https://www.radiantinsights.com/research/complementary-and-alternative-medicine-market

In addition, increase in the number of licensed and trained physicians who can offer state-of-the-art complementary therapies is set to boost patient preference toward traditional medicine. It is becoming integral in the healthcare system in Asia, especially in China wherein most of the hospitals in the country have distinct departments and wards that are dedicated to traditional therapeutic approaches.

Moreover, in terms of research, CAM has reached a remunerative stage. This can be attributed to the rising pool of scientists working at established universities across U.S., Europe, and Asia Pacific who are focusing on building a robust foundation for the alternative treatment targeted toward Parkinson’s disease, cancer, and diabetes.

Further key findings from the report suggest:

• Botanicals are the most ancient form of alternative treatment practices, which include herbal and natural treatment supplements along with another natural form of treatments incorporating oils, herbs, and other curative supplements

• The botanicals intervention segment dominated the global market throughout the study period, whereas magnetic intervention is expected to grow at the fastest rate from 2020 to 2027

• Mind and body healing oriented traditional medicines are some of the most frequently adopted forms of alternate therapies worldwide. Mind and body intervention incorporates various forms of energy and mind exercises to heal ailments

• Yoga has dominated the global complementary and alternative medicine market throughout the study period, whereas hypnotherapy is projected to witness the highest growth rate over the forecast period

• Europe is anticipated to witness highest market share over the forecast period. Rising preference for alternative treatment approaches among patients will drive the regional market for complementary and alternative medicine.

• Key industry participants include Nordic Nutraceuticals, Pure encapsulations, LLC, AYUSH Ayurvedic Pte Ltd, and Sheng Chang Pharmaceutical Company

• Companies are inclined toward strategic partnerships to establish their presence in the market; for instance, in June 2019, AstraZeneca partnered with Luye Pharma Group to market a herbal therapy

• The herbal medicine product is developed from red yeast rice and is formulated to assist patients suffering from cholesterol. With this partnership, AstraZeneca is set to expand its business across China.

Download free request sample :
https://www.radiantinsights.com/research/complementary-and-alternative-medicine-market/request-sample

Global behavioral/mental health care software and services market size is expected to reach USD 5.0 billion by 2027

March 19, 2020 - The global behavioral health care software and services market size is expected to reach USD 5.0 billion by 2027. It is anticipated to register a CAGR of 11.1% during the forecast period. Behavioral health management software provides ease of communication between care providers and patients and its real-time monitoring feature enables doctors to efficiently track patient progress.

These systems maintain confidentiality regarding patient information, especially in cases of substance abuse and mental health. The software increase productivity and efficiency of mental healthcare, by integrating with its existing infrastructure. Behavioral healthcare providers help reduce treatment costs by providing value-based medicine programs, thus preventing hospital readmissions. The impact of substance abuse is estimated to be worth USD 600 billion every year in U.S., according to a survey by the Substance Abuse and Mental Health Services Administration (SAMHSA).

The Cures Act provides the vendors with an opportunity of integrating, resulting in the care coordination of both parties. The act will enable interoperability between healthcare providers, especially mental healthcare providers, enable insurance claim submissions, simplify the explanation of benefits, and eliminate the obstacles to reimbursement for faster returns. New behavioral health integration codes were introduced by the Centers for Medicare & Medicaid Services (CMS) under the psychiatric collaborative care model and behavioral health integration under the successful chronic care management services initiative.

Further key findings from the report suggest:

• The software segment held the largest market share in 2019, due to increasing adoption of technological solutions by mental healthcare providers for managing the financial, administrative, and clinical functions

• Subscription services dominated the delivery model segment in 2019 in terms of revenue share. Due to limited budgets and small practice scale, the small-scale mental health practices prefer subscription-based software solutions

• Clinical functions dominated the function segment in 2019 in terms of revenue share. The integration of clinical functions reduces the workload on the mental health care facilities and improves productivity

• North America accounted for the largest market share in 2019 and Asia Pacific is expected to witness the fastest growth over the forecast period

• Partnerships between local health systems and rising integrated care model adoption are expected to create growth opportunities for the behavioral/mental health care software and services market

• Some of the key market players in behavioral health care software and services are Welligent, Inc.; Netsmart Technologies; Epic; Core solutions, Inc.; and Cerner Corporation

Research Antibodies Market Analysis By Type (Monoclonal, Polyclonal) and Forecasts to 2027

Feb 26, 2020 - The global research antibodies market size is expected to reach USD 5.6 billion by 2027, exhibiting a CAGR of 6.2% over the forecast period. Major market drivers include rise in R&D initiatives undertaken by biopharmaceutical and biotechnology companies and government bodies, growing interest in the study of neurobiology and stem cell, availability of technologically advanced products, and strategic collaborations among various market players and academic research organizations.

Designer antibodies are also anticipated to attract the attention of various academic organizations for their use in the R&D of novel products. For instance, in April 2019, scientists from ALS Canada Research Program developed a set of antibodies that can help in the detection of misfolded TDP-43 in various lab experiments that utilize post-mortem brain tissues. Rising usage of research antibodies for the development of novel diagnostic therapies is thus anticipated to fuel market growth in the near future.

In-Depth research report on Research Antibodies market:   
https://www.radiantinsights.com/research/research-antibodies-market

Increase in the usage of research antibodies to develop treatment options for various diseases is also expected to boost market growth during the forecast period. For instance, in June 2019, the Institute of Life Sciences (ILS, India) developed antibodies against chikungunya viral infection. These antibody structures were developed to aid in the understanding of various aspects of virus pathogenesis, entailing further research on antiviral therapies. Growing government funds and initiatives for R&D is anticipated to fuel the Asia Pacific market during the forecast period. According to the 2018-2019 Australian Budget, approximately USD 94 million was estimated for four years for new industry collaborations, research as well as new biomedical and medical programs.

Additionally, rise in funds invested by pharmaceutical and biotechnology companies to enhance the study of proteomics and genomics is expected to drive the market. For instance, in 2017, Biognosys Inc. raised USD 5 million in funds to increase, advance, and develop next-generation proteomics products and workflow for high throughput and high content protein analysis. Rise in the number of major market players investing in advanced technologies and collaborating with other market players is also anticipated to positively impact market potential in the near future. For instance, Abcellera uses technologically advanced techniques to test antibodies from single B cells, map and screen natural immune responses, and to discover novel antibody therapies. The company has also partnered with Sanofi, Pfizer, Teva, Merck, and GSK to discover and develop new antibody-based therapies.

North America dominated the research antibodies market in owing to increasing focus on R&D in the fields of biomedicine, stem cell, and cancer. Rising prevalence of chronic diseases such as cardiovascular and blood diseases is also expected to fuel market growth.

Launch of novel antibody structures for diagnosis of various diseases is also a major factor expected to boost the market. For instance, in August 2018, BioGenex launched a range of new antibodies for its use in cancer immunohistochemistry. The company’s immunohistochemistry solution offers about 400 reagents, primary antibodies, consumables, and ancillaries.  Key players in the market include Abcam Plc; Bio-Rad Laboratories Inc.; PerkinElmer, Inc.; Agilent Technologies; Roche; Cell Signalling Technology, Inc.; Thermo Fisher Scientific; Lonza Group; and BD.

Further key findings from the report suggest:

• By product, primary antibodies held the dominant share in 2019 in terms of revenue owing to greater specificity, therefore leading to increased adoption in R&D activities         

• Based on type, monoclonal antibodies captured a substantial market share in 2019 as they offer higher sensitivity for detection of antigens and also showcase efficient staining properties for various applications

• The Western blotting technology segment has witnessed exponential growth owing to increasing prevalence of diseases with limited treatment options and rise in R&D activities conducted by pharmaceutical and biotechnology companies and academic institutes

• Based on end use, pharmaceutical and biotechnology companies were dominant in terms of revenue in 2019 owing to increased adoption of research antibodies in drug development and discovery

• North America accounted for a substantial share of the research antibodies market in 2019, which is attributable to high presence of many biotechnologies as well as biopharmaceutical manufacturers, research academies, and laboratories.

To get a free sample request at:
https://www.radiantinsights.com/research/research-antibodies-market/request-sample

Live cell imaging is used as a popular tool for biological mechanisms and contributes significantly to the functions of multiple cellular processes

February 13, 2019 - According to a report available on Radiant Insights, Inc.; the global live cell imaging market is projected to witness a healthy CAGR by 2022. High prevalence of cancer and growing government backing in cell-based research are anticipated to propel growth. Increasing use of high-content screening techniques in drug discovery can further boost market growth over the forecast period (2018 to 2022).

Browse full research report :
https://www.radiantinsights.com/research/live-cell-imaging-market-outlook-2022

Rising preference for kinetic research over fixed cellular analysis is considered as one of the major driving factors for market. Addition of dyes and reagents alter the cell behavior, generally in a negative manner and do not display the natural cellular functions. In drug discovery phase, understanding the cellular behavior in its natural state is crucial. The technique is used to study cellular integrity, enzyme activity, exocytosis and endocytosis protein trafficking, and localization of molecules. It is also used to monitor molecules in live animals. Increasing adoption in development of personalized medicine is expected to create growth opportunities  over the forecast period.

However, factors such as high cost of high-content screening systems and lack of skilled professionals are expected to restrain growth of the market for live cell imaging over the forecast period.

The worldwide live cell imaging market can be segmented on the basis of product, application, technology, and region. Based on product, the market can be categorized into equipment, consumables, and software. As per application, the market can be divided into cell biology, stem cell biology, developmental biology, drug discovery, and others. On the basis of technology, the market can be split into Fluorescent Resonance Energy Transfer (FRET), High Content Analysis (HCA), Fluorescence In Situ Hybridization (FISH), and others.

Geographically, the market can be divided into North America, Europe, Asia Pacific, and Rest of the World (RoW). Europe and North America are the early adaptors of live cell imaging technology. Governments in these regions are making significant investments in research and development activities. North America is the major market due to the presence of technologically advanced infrastructure and rising investments.

In Europe, increasing demand for research regarding cardiac diseases, neurodegeneration, and cancers has lead to development of stem cell research and advanced microscopy. This factor is anticipated to propel regional growth over the forecast period. Increasing funding for R&D in cell and developmental biology from institutes like Wellcome Trust and Cancer Research U.K. are also supporting growth in this region. Asia Pacific is likely to showcase rapid CAGR due to high demand from India and China. Increasing scope of live cell imaging in drug discovery and personalized medicines is expected to further support regional market growth.

To get free request sample :
https://www.radiantinsights.com/research/live-cell-imaging-market-outlook-2022/request-sample

Key companies operating in the global live cell imaging market include Perkin Elmer, Inc.; GE Healthcare; Becton Dickenson & Co.; Nikon Instruments Inc.; and Danaher Corporation. The market is extremely competitive with major dominant companies focusing on new product launches, partnerships, and mergers and acquisition to sustain competition.

For instance, GE Healthcare recently launch DeltaVision Ultra microsystem. The system a high-resolution widefield deconvolution microscope designed for widefield fluorescence imaging and analysis of cellular and subcellular processes, up to 50 μm beyond the coverslip and down to 250nm in size. It contains ergonomically designed environmental chamber united with gas control, which supports live cell imaging analysis under physiological conditions and complex non-physiological conditions like hypoxia.

Healthcare Supply Chain Market Trends, Leading Players, Technological Innovations, Key Developments, and Future Strategies

November 27, 2018 - The global Healthcare Supply Chain Market is anticipated to grow at substantial CAGR during the forecast period (2018 to 2025), according to a report available on Radiant Insights, Inc. Growing requirement for high-quality medical care in terms of facilities and services among patients is anticipated to propel demand for healthcare supply chain management. It is likely to support healthcare providers to reduce costs related to expensive delivery of quality services by eliminating waste and improving operations.  

Browse full research report :

https://www.radiantinsights.com/research/global-healthcare-supply-chain-market-size-status-and-forecast-2025

Rising focus on supply chain management by healthcare sector to effectively reduce costs is expected to influence growth of market. Continual efforts to deliver high-quality services to consumers by healthcare manufacturers can augment market growth. Growing penetration and adoption of several components such as cloud-based solutions and software can spur growth of market. Rising adoption of e-commerce solutions to eliminate error-prone manual processes from supply chain and reduce process can surge market growth. Continual technological advancement in healthcare supply chain management can impel market growth during the forecast period (2018 to 2025).

To cater to rising demand for healthcare supply chain management, most companies are likely to focus on R&D activities to develop advanced software and hardware. For instance, McKesson is expected to offer web-based order management system named Supply Manager. This system is likely to allow users to place medical supply orders and control costs. Users can place orders online, view real-time pricing & availability, view order status, and run reports to analyze purchasing trends. With connectivity to company’s procurement and practice management system, Supply Manager can provide efficient, informed management of user’s medical and surgical supply ordering along with inventory management. 

The healthcare supply chain market can be segregated on the basis of product, application, and region. Based on product, the market can be categorized into software and hardware. In recent years, software segment dominated the market and accounted for largest market share. Growing adoption of healthcare supply chain management software among manufacturing companies can influence growth of segment. In addition, increasing applications such as customer relationship management and execution of value chain transactions can fuel market growth. The segment is likely to grow at high CAGR over the forecast period. 

Based on end-users, the market can be classified into providers, manufacturers, and distributors. In recent years, manufacturers segment dominated the market and accounted for largest market share. However, providers segment is estimated to account for high CAGR during the forecast period. The segment is likely to include hospitals and other service providers.

Regional segmentation includes Europe, United States, India, Japan, China, and Southeast Asia. United States is expected to account for largest market share over the forecast period attributed to growing adoption of technology coupled with increased purchasing power. In addition, high prevalence of global players coupled with rising concerns of cost of healthcare can augment growth of market over next few years.

Similarly, Europe is anticipated to account for second largest market share led by countries such as United Kingdom, Germany, and France over the forecast period. However, market is expected to shift in favor of developing economies such as Japan, India, and China during the forecast period.

Free request sample :

https://www.radiantinsights.com/research/global-healthcare-supply-chain-market-size-status-and-forecast-2025/request-sample

In Middle East and Africa, the market is expected to witness moderate growth owing to poor economic and political conditions in Africa.

Some of the leading companies offering healthcare supply chain are McKesson, Oracle Corporation, HighJump, Manhattan Associates, and Jump Technologies.

Artificial Knee Implants to Alleviate Joint Pain

Rising incidence of rheumatoid arthritis, joint pain, and other bone-related disorders have pushed the demand of artificial knee implants. Artificial knee implants can provide relief to patients suffering from persistent joint pain, especially the growing geriatric populace. Improvements in implant designs and use of biocompatible materials to extend the life of implants can popularize minimally invasive surgeries.

Browse full research report :

https://www.radiantinsights.com/research/global-artificial-knee-implant-market-research-report-2018

Advent of 3D printing has made it possible to create customized implants according to gender or bone shape and size. Computer assisted surgery (CAS) and robotic assisted surgery are methods gaining prominence by performing successful surgeries and reduce patient recovery rate.

Customized Implants and Robotic Assistance

Types of surgical procedures for artificial knee implants are segmented into partial, total, and revision.

The total knee replacement (TKR) segment is expected to generate bigger revenues compared to its counterparts due to high demand for these surgeries in Germany and U.S. Advances in surgical procedures and their subsequent demand in developing economies are projected to spur segment demand in the forthcoming years. This is exemplified by the 100,000th successful surgery of the Mako System, a robotic assistant, by Stryker Corporation in 2017.

The partial knee replacement (PKR) segment is projected to gain good returns due to increasing incidence of unicompartmental knee osteoarthritis (UKOA). Improvements in implant designs and utilization of robots to increase surgical outcomes can augur segment demand in the forthcoming years. In 2017, Zimmer Biomet Holdings launched the Persona Partial Knee System to cater to patients demand for personalized implants.

Market Outlook

The artificial knee implant market is set to expand at a phenomenal growth rate in the forthcoming years, as per a report on Radiant Insights, Inc.  Rise in market demand can be attributed to the growing geriatric populace, preference of minimally invasive surgeries (MIS), and prevalence of arthritis. Increasing investments in the healthcare sector in China and India can open up new opportunities for players in the near future. Price caps placed on knee implants in developing economies can lead to its implementation in hospitals. Key market players include B. Braun Melsungen AG; Zimmer Biomet Holdings, Inc.; Stryker Corporation; and Smith & Nephew plc.

Request free sample :

https://www.radiantinsights.com/research/global-artificial-knee-implant-market-research-report-2018/request-sample

Artificial insemination is usually the preferred first-line treatment for infertility

The global artificial insemination market is expected to reach USD 2.63 billion by 2025. Over the past few years, infertility has become a major public health concern across the globe. Artificial insemination is usually the preferred first-line treatment for infertility. According to WHO, around 10% of women in the world are struggling to get pregnant. Lifestyle changes, delay in pregnancy, and hormonal issues are some of the reasons contributing to the rise in infertility around the world.

The exact estimation of infertility statistics is challenging, however, WHO monitors its prevalence across the world. At present, 46% of the global population lives in countries having low levels of fertility. According to United Nations, the global rate of fertility is expected to decline to 2.4 by 2030 and 2.2 by 2050. In developing or underdeveloped nations, medical consultation regarding infertility and childlessness was not easily accessible. Hence, there was lack of awareness about available assisted reproductive techniques including artificial or donor insemination and IVF.

Further key findings from the report suggest:

• Artificial insemination is a first-line infertility treatment as it is minimally invasive and less expensive as compared to IVF

• It is preferred mostly by single women who wish to conceive and same-sex partners with the help of fresh or frozen donor sperm samples. In some countries, lesbian couples are provided insurance coverage for these procedures

• Intrauterine Insemination (IUI) held majority of the market share in 2017 and is likely to be the fastest-growing segment over the forecast period, as it is the most common and noninvasive procedure.

• Fertility clinics held majority of the market share in 2017 as the number of medical facilities offering infertility treatments has been increasing over the past decade

• Fertility clinics provide medical consultation regarding the detection of ovulation to perform the procedure for insemination. Sperm washing is also performed in the clinics to achieve optimum results

• Artificial insemination with partner's or (AIH) sample held the majority of the source type segment share

• Europe held majority of the market share in 2017 due to the presence of the largest number of patients and easily accessible treatment options

• On the other hand, Asia Pacific is expected to be the fastest-growing regional market due to increase in awareness regarding artificial or donor insemination in the region

• Some of the key players in this market include Irvine Scientific; Rinovum Women's Health, LLC; TenderNeeds Fertility; Conceivex, Inc.; Hi-Tech Solutions; among others.

To get free request sample :

https://www.radiantinsights.com/research/artificial-insemination-market/request-sample